Korro Bio, Inc. (KRRO)

36.17 -2.15 (-5.61%) As of 01:40PM EDT. Market open.

Korro Bio, Inc.

One Kendall Square
Building 600-700 Suite 6-401
Cambridge, MA 02139
United States
617 468 1999
https://www.korrobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 94

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nessan Bermingham Ph.D.	Co-Founder & Independent Chairman of the Board	202.14k	N/A	1973
Mr. Ram Aiyar MBA, Ph.D.	CEO, President & Director	844.87k	N/A	1978
Dr. Jean-Francois Formela M.D., MBA	Co-Founder & Independent Director	8.21k	N/A	1957
Mr. Vineet Agarwal M.B.A.	Chief Financial Officer	811.77k	N/A	1982
Dr. Steven L. Colletti Ph.D.	Chief Scientific Officer	592.89k	N/A	1966
Mr. Andrew Fraley Ph.D.	Co-Founder & Advisor	N/A	N/A	N/A
Dr. Joshua Rosenthal Ph.D.	Co-Founder & Advisor	N/A	N/A	N/A
Mr. Todd Chappell M.B.A.	Chief Operating Officer	N/A	N/A	1973
Ms. Shelby Walker J.D.	Senior VP, General Counsel & Corporate Secretary	N/A	N/A	1975
Ms. Stephanie Engels	Senior VP and Head of People & Culture	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Corporate governance

Korro Bio, Inc.’s ISS governance QualityScore as of 1 July 2024 is 9. The pillar scores are Audit: 3; Board: 10; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.